Insight Molecular Diagnostics (IMDX) Cash & Equivalents (2020 - 2025)
Insight Molecular Diagnostics (IMDX) has disclosed Cash & Equivalents for 6 consecutive years, with $11.6 million as the latest value for Q4 2025.
- Quarterly Cash & Equivalents rose 34.12% to $11.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.6 million through Dec 2025, up 34.12% year-over-year, with the annual reading at $11.6 million for FY2025, 34.12% up from the prior year.
- Cash & Equivalents hit $11.6 million in Q4 2025 for Insight Molecular Diagnostics, down from $18.7 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $58.9 million in Q1 2021 to a low of $433000.0 in Q4 2022.
- Historically, Cash & Equivalents has averaged $21.0 million across 5 years, with a median of $18.0 million in 2023.
- Biggest five-year swings in Cash & Equivalents: plummeted 98.69% in 2022 and later skyrocketed 2078.29% in 2023.
- Year by year, Cash & Equivalents stood at $32.9 million in 2021, then tumbled by 98.69% to $433000.0 in 2022, then surged by 2078.29% to $9.4 million in 2023, then fell by 8.44% to $8.6 million in 2024, then soared by 34.12% to $11.6 million in 2025.
- Business Quant data shows Cash & Equivalents for IMDX at $11.6 million in Q4 2025, $18.7 million in Q3 2025, and $24.3 million in Q2 2025.